| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Meropenem trihydrate (SM-7338; ICI-194660; SM7338; ICI194660; Vabomere; Merrem), the trihydrated form of meropenem which is a beta-lactam antibiotic of the carbapenem class, is an ultra-broad-spectrum injectable β-lactam antibiotic used to treat a wide variety of infections.
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
Meropenem functions by binding to and deactivating penicillin-binding proteins (PBPs), thereby inhibiting the synthesis of bacterial cell walls. Meropenem is intrinsically stable against dehydropeptidase-1 (DHP-1) degradation. While Meropenem exhibits broad-spectrum in vitro activity against a variety of Gram-positive, Gram-negative, and anaerobic bacteria, it is ineffective against methicillin-resistant Staphylococcus aureus, Enterococcus faecium, and Stenotrophomonas maltophilia[2].
|
| ln Vivo |
The incidence of pancreatic infection is significantly reduced by treatment with meropenem (60 mg/kg; intraperitoneal injection; once; SD rats)[3].
|
| Animal Protocol |
Animal Model: Acute necrotizing pancreatitis was induced in male Sprague-Dawley rats weighing 250–350 g.
Dosage: 60 mg/kg Administration: Intraperitoneal injection; once Result: The incidence of pancreatic infection was significantly decreased. |
| References |
| Molecular Formula |
C17H31N3O8S
|
|---|---|
| Molecular Weight |
437.51
|
| Elemental Analysis |
C, 46.67; H, 7.14; N, 9.60; O, 29.25; S, 7.33
|
| CAS # |
119478-56-7
|
| Related CAS # |
Meropenem;96036-03-2;Meropenem-d6;1217976-95-8
|
| Appearance |
Solid powder
|
| SMILES |
O=C(C(N12)=C(S[C@@H]3CN[C@H](C(N(C)C)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O.[H]O[H].[H]O[H].[H]O[H]
|
| InChi Key |
CTUAQTBUVLKNDJ-OBZXMJSBSA-N
|
| InChi Code |
InChI=1S/C17H25N3O5S.3H2O/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);3*1H2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1
|
| Chemical Name |
(4R,5S,6S)-3-(((3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate
|
| Synonyms |
Meropenem trihydrate; Meropenem hydrate; ICI 194660; ICI-194660; ICI194660; SM-7338; SM 7338; SM7338; Vabomere.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~228.57 mM)
H2O : ~12.5 mg/mL (~28.57 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (228.57 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2857 mL | 11.4283 mL | 22.8566 mL | |
| 5 mM | 0.4571 mL | 2.2857 mL | 4.5713 mL | |
| 10 mM | 0.2286 mL | 1.1428 mL | 2.2857 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
